Immunotherapy

This page covers all Immunotherapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-L1, PD-1/PD-L1, T-lymphocytes.

Targets

PD-L1 · PD-1/PD-L1 · T-lymphocytes

Marketed (3)

• The MP/RP group · Beijing Tiantan Hospital · Immunology
  The MP/RP group is a type of immunotherapy that targets the immune system to treat various conditions.
• Escalation Therapies Group · The Cleveland Clinic · Oncology
  Escalation Therapies Group involves gradually increasing the intensity of a treatment to achieve a desired therapeutic effect.
• Pf-06835375 · Pfizer · Oncology

Phase 2 pipeline (3)

• Fecal Microbiota Transplant with Pembrolizumab · Zarour, Hassane, MD · Oncology
  Fecal microbiota transplant modulates the gut microbiome to stimulate an anti-tumor immune response through PD-1/PD-L1 pathway.
• Epicutaneous Immunotherapy · Assistance Publique - Hôpitaux de Paris · Immunology
  Allergen exposure to induce immune tolerance
• Application of T-lymphocytes · Hannover Medical School · Immunology
  Application of T-lymphocytes targets the immune system

Phase 1 pipeline (1)

• ALECSAT cell based immunotherapy · CytoVac A/S · Oncology
  Cell-based immunotherapy targeting cancer cells